Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

It's a good idea to go against the current market sentiment on this one. Vertex Pharmaceuticals continues to generate most of its revenue from its cystic fibrosis (CF) franchise. The company's ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Secondary lymphoid organs (SLOs) are the central organizing platform for the immune system's daily 'business': coping with infectious challenges from the environment. The following functional building ...

What Is SEC Form D? SEC Form D is required for companies selling securities under Regulation (Reg) D or Section 4(a)(5) exemptions. Form D provides basic information about the company for investors.